Antipsychotics of interest to the National Pregnancy Registry include:
- Abilify (aripiprazole)
- Aristada (aripiprazole lauroxil)
- Aristada Initio (aripiprazole lauroxil)
- Caplyta (lumateperone)
- Geodon (ziprasidone)
- Invega (paliperidone)
- Latuda (lurasidone)
- Lybalvi (olanzapine & samidorphan)
- Rexulti (brexpiprazole)
- Risperdal (risperidone)
- Seroquel (quetiapine)
- Symbyax (olanzapine & fluoxetine)
- Zyprexa (olanzapine)
Required Sponsorship Disclosures:
Current Sponsors: Alkermes, Inc. (2016-Present); Dr. Reddy’s Laboratories, Inc. (2023-Present); Eisai Inc. (2022 – Present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-Present); Supernus Pharmaceuticals (2021-Present); Teva Pharmaceutical Industries Ltd. (2018-Present).
Past Sponsors: Forest/Actavis/Allergan (2016-2018, declined to sponsor: 2018-Present); Aurobindo Pharma (2020-2022, declined to sponsor: 2022-Present); AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); AuroMedics Pharma LLC (2021-2022, declined to sponsor: 2022-Present); Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009-2011, declined to sponsor: 2012-Present); Sunovion Pharmaceuticals, Inc. (2011-2023).
Declined to sponsor: AbbVie Inc.; Apotex Inc.; Arcolab Private Limited; Eli Lilly and Company; Intra-Cellular Therapies, Inc.; Novartis Pharmaceuticals; Qilu Pharmaceutical Co., Ltd.; Vanda Pharmaceuticals Inc.
Funding Information: Manufacturers of psychiatric medications have been approached regarding funding of the National Pregnancy Registry. Regardless of which entities have supported this initiative, all medications in this class are studied. For more information on how to sponsor the Registry, please see the contact information below.